Bruker Corporation $BRKR Shares Purchased by Vaughan Nelson Investment Management L.P.

Vaughan Nelson Investment Management L.P. boosted its position in shares of Bruker Corporation (NASDAQ:BRKR) by 71.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,293,645 shares of the medical research company’s stock after buying an additional 537,845 shares during the quarter. Vaughan Nelson Investment Management L.P. owned approximately 0.85% of Bruker worth $53,298,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sculptor Capital LP grew its position in Bruker by 51.6% during the first quarter. Sculptor Capital LP now owns 2,598,438 shares of the medical research company’s stock valued at $108,459,000 after buying an additional 884,423 shares during the period. Brown Advisory Inc. grew its position in Bruker by 18.9% during the first quarter. Brown Advisory Inc. now owns 2,410,137 shares of the medical research company’s stock valued at $100,599,000 after buying an additional 383,425 shares during the period. AQR Capital Management LLC grew its position in Bruker by 65.9% during the first quarter. AQR Capital Management LLC now owns 1,476,605 shares of the medical research company’s stock valued at $60,688,000 after buying an additional 586,516 shares during the period. Goldman Sachs Group Inc. grew its position in Bruker by 107.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after buying an additional 758,301 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Bruker by 5.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 926,790 shares of the medical research company’s stock valued at $38,684,000 after buying an additional 50,537 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Performance

BRKR opened at $36.98 on Friday. The firm has a market capitalization of $5.61 billion, a PE ratio of 71.12, a PEG ratio of 4.84 and a beta of 1.20. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $67.42. The firm’s 50-day moving average price is $33.51 and its 200 day moving average price is $37.52. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The business had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business’s revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.52 earnings per share. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, sell-side analysts expect that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd were given a dividend of $0.05 per share. The ex-dividend date was Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s payout ratio is presently 38.46%.

Insiders Place Their Bets

In other Bruker news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director directly owned 18,016 shares of the company’s stock, valued at $581,016. The trade was a 16.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 27.30% of the company’s stock.

Wall Street Analysts Forecast Growth

BRKR has been the topic of several analyst reports. Barclays dropped their price target on shares of Bruker from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday. Stifel Nicolaus set a $40.00 target price on shares of Bruker and gave the company a “hold” rating in a research report on Tuesday, August 5th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research report on Saturday, September 27th. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the company a “buy” rating in a research report on Monday, August 4th. Finally, Wells Fargo & Company dropped their target price on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 5th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $51.00.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.